Literature DB >> 2086490

Possible role of IL-6 in pathogenesis of immune complex-mediated glomerulonephritis in NZB/W F1 mice: induction of IgG class anti-DNA autoantibody production.

M Mihara1, Y Ohsugi.   

Abstract

This study demonstrates that interleukin-6 (IL-6) increases the autoantibody production by B cells from NZB/W F1 mice. Splenic B cells were cultured for 5 days in the presence or absence of human IL-6, and then the anti-DNA antibody and immunoglobulin contents in the culture supernatants were measured by ELISA. Adding IL-6 increased IgG anti-DNA antibody production by B cells from old mice (30 weeks), but not from young ones (17 weeks). B cells obtained from both young and old mice produced IgM anti-DNA antibody, which increased when IL-6 was added. The increased anti-DNA antibody production was suppressed by anti-recombinant human IL-6 antibody to the background level, i.e. antibody contents in the absence of IL-6. In contrast, murine IL-5 did not increase IgG anti-DNA antibody production, although it promoted the production of IgM anti-DNA antibody. Furthermore, when IL-5 was added in combination with IL-6, there was an additive increase in IgM, but not in IgG anti-DNA antibody production. Similar results were obtained in the measurement of the immunoglobulin contents. These results suggest the possible role of IL-6 in the pathogenesis of autoimmune disease in NZB/W F1 mice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2086490     DOI: 10.1159/000235285

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  8 in total

1.  IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice.

Authors:  Zheng Liu; Ramalingam Bethunaickan; Weiqing Huang; Meera Ramanujam; Michael P Madaio; Anne Davidson
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

2.  Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice.

Authors:  M Mihara; Y Koishihara; H Fukui; K Yasukawa; Y Ohsugi
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

Review 3.  Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Authors:  E Tackey; P E Lipsky; G G Illei
Journal:  Lupus       Date:  2004       Impact factor: 2.911

4.  IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice.

Authors:  M Mihara; N Takagi; Y Takeda; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

5.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

6.  Interleukin 6 Accelerates Mortality by Promoting the Progression of the Systemic Lupus Erythematosus-Like Disease of BXSB.Yaa Mice.

Authors:  Shweta Jain; Giljun Park; Thomas J Sproule; Gregory J Christianson; Caroline M Leeth; Hongsheng Wang; Derry C Roopenian; Herbert C Morse
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

Review 7.  Translating IL-6 biology into effective treatments.

Authors:  Ernest H Choy; Fabrizio De Benedetti; Tsutomu Takeuchi; Misato Hashizume; Markus R John; Tadamitsu Kishimoto
Journal:  Nat Rev Rheumatol       Date:  2020-04-23       Impact factor: 20.543

8.  Isolevuglandins disrupt PU.1-mediated C1q expression and promote autoimmunity and hypertension in systemic lupus erythematosus.

Authors:  David M Patrick; Néstor de la Visitación; Jaya Krishnan; Wei Chen; Michelle J Ormseth; C Michael Stein; Sean S Davies; Venkataraman Amarnath; Leslie J Crofford; Jonathan M Williams; Shilin Zhao; Charles D Smart; Sergey Dikalov; Anna Dikalova; Liang Xiao; Justin P Van Beusecum; Mingfang Ao; Agnes B Fogo; Annet Kirabo; David G Harrison
Journal:  JCI Insight       Date:  2022-07-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.